Document Detail

Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
MedLine Citation:
PMID:  18219812     Owner:  NLM     Status:  MEDLINE    
This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5-10 years have a very small risk of developing disability over the next 10-20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available disease-modifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population.
S J Pittock; M Rodriguez
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current topics in microbiology and immunology     Volume:  318     ISSN:  0070-217X     ISO Abbreviation:  Curr. Top. Microbiol. Immunol.     Publication Date:  2008  
Date Detail:
Created Date:  2008-01-28     Completed Date:  2008-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0110513     Medline TA:  Curr Top Microbiol Immunol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1-17     Citation Subset:  IM    
Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Brain / radiography
Interferon-beta / therapeutic use*
Magnetic Resonance Imaging
Mitoxantrone / therapeutic use*
Multiple Sclerosis / drug therapy*,  physiopathology*,  radiography
Peptides / therapeutic use*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Peptides; 0/copolymer 1; 0/natalizumab; 65271-80-9/Mitoxantrone; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of copper metal on the yield of Sc3N@C80 metallofullerenes.
Next Document:  Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders...